NCT00311389

Completed

Phase 3

A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

Alcon Research1 site in 1 country408 target enrollmentJanuary 2003

ConditionsGlaucoma, Open-angle Ocular Hypertension

InterventionsTravoprost 0.004%/Timolol maleate 0.5% ophthalmic solution Latanoprost 0.005%/Timolol 0.005% ophthalmic solution

DrugsTravoprost 0.004%/Timolol maleate 0.5% ophthalmic solution Latanoprost 0.005%/Timolol 0.005% ophthalmic solution

Overview

Phase: Phase 3
Intervention: Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution
Conditions: Glaucoma, Open-angle
Sponsor: Alcon Research
Enrollment: 408
Locations: 1
Primary Endpoint: Mean Intraocular Pressure (IOP)
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the intraocular pressure(IOP)-lowering efficacy of a combination IOP-lowering therapy in patients with open-angle glaucoma or ocular hypertension.

Registry

clinicaltrials.gov

Start Date

January 2003

End Date

September 2004

Last Updated

14 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Alcon Research

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•As specified in protocol

Exclusion Criteria

•As specified in protocol

Arms & Interventions

Travoprost/Timolol

1 drop in the affected eye(s) once daily in the morning for 12 months

Intervention: Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution

Latanoprost/Timolol

1 drop in the affected eye(s) once daily in the morning for 12 months

Intervention: Latanoprost 0.005%/Timolol 0.005% ophthalmic solution

Outcomes

Primary Outcomes

Mean Intraocular Pressure (IOP)

Time Frame: 12 months

Study Sites (1)

Loading locations...

Similar Trials

Completed

Phase 2

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular HypertensionOpen-Angle GlaucomaOcular Hypertension

NCT00761709Alcon Research104

Completed

Phase 2

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle GlaucomaOpen-angle Glaucoma

NCT00451152Alcon Research89

Completed

Phase 2

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle GlaucomaPrimary Open-Angle Glaucoma (POAG)Ocular Hypertension (OHT)

NCT01917383Inotek Pharmaceuticals Corporation101

Completed

Phase 4

Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)Angle-closure Glaucoma

NCT00762645Alcon Research30

Completed

Not Applicable

One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma SubjectsPrimary Open Angle Glaucoma (POAG)

NCT01517477Glaukos Corporation119